Payment overview · 2025
General Payments
$120.63
5 reported records · 5 companies
Healthcare provider profile · identity verified
Denia E. Gonzalez, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOROVIS, PR · NPI 1124080718
Verified facts
What the public records show
CMS Open Payments records show Denia E. Gonzalez, MD received $120.63 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xarelto by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 147 records involving 126 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.03 | 24.1% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $23.87 | 19.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.63 | 19.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.70 | 18.8% | 1 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $21.40 | 17.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.63 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PBG PUERTO RICO LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PBG PUERTO RICO LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PBG PUERTO RICO LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PBG PUERTO RICO LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $21.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
240 | 60 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 147 supporting records · 126 recipient NPIs · example record 1228798592 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 465 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 117 |
| Lisinopril | Lisinopril | 317 | 84 |
| Synthroid | Levothyroxine Sodium | 240 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 70 |
| Metformin Hcl | Metformin Hcl | 215 | 55 |
| Omeprazole | Omeprazole | 206 | 43 |
| Losartan Potassium | Losartan Potassium | 198 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 55 |
| Famotidine | Famotidine | 195 | 37 |
| Furosemide | Furosemide | 138 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 42 |
| Ciclopirox | Ciclopirox | 127 | 38 |
| Simvastatin | Simvastatin | 126 | 31 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 122 | 22 |
| Alendronate Sodium | Alendronate Sodium | 113 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 16 |
| Humalog | Insulin Lispro | 93 | 16 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 86 | 17 |
| Meclizine Hcl | Meclizine Hcl | 85 | 33 |
| Glipizide | Glipizide | 82 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 23 |
| Glimepiride | Glimepiride | 71 | 19 |
| Farxiga | Dapagliflozin Propanediol | 69 | 16 |
| Humulin N | Insulin Nph Human Isophane | 69 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 67 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 14 |
| Sure Comfort | Syringe And Needle,insulin,1ml | 63 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 16 |
| Carvedilol | Carvedilol | 54 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 15 |
| Spironolactone | Spironolactone | 52 | 11 |
| Latanoprost | Latanoprost | 50 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Allopurinol | Allopurinol | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Finasteride | Finasteride | 39 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 35 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 33 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 28 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Naproxen | Naproxen | 22 | 13 |
| Nabumetone | Nabumetone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Sulindac | Sulindac | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lamictal | Lamotrigine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.63 · 5 records | ABBVIE INC. | ABRYSVO, COMIRNATY, ELIQUIS, INVEGA SUSTENNA, MOUNJARO, PENBRAYA, PREVNAR 20, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error